Literature DB >> 9158710

Loss of heterozygosity in usual and special variant carcinomas of the endometrium.

D Tritz1, M Pieretti, S Turner, D Powell.   

Abstract

Endometrial carcinoma is the most common invasive malignancy of the female genital tract, and it exists as two different clinicopathologic forms: an estrogen-dependent, "usual" type and an estrogen-independent "special variant" type. Despite the frequency of endometrial cancer, little is known about the molecular genetic events that contribute to its pathogenesis. The accumulation of genetic alterations identified through the study of loss of heterozygosity (LOH), gene mutation, and gene activation in tumor DNA has been associated with the establishment and progression of a variety of human malignancies. A relatively low incidence of LOH has been reported in usual type endometrial cancers; however, special variant tumors have rarely been included in the reported studies. To understand the molecular events that contribute to both forms of endometrial cancer, 31 tumors have been surveyed for events of LOH on all chromosomes. The study groups included 18 tumors of the usual type and 13 special variant tumors. Polymorphic loci were studied by Southern blot analysis and polymerase chain reaction (PCR) of microsatellite loci. Normal tissue in each case served as a control. Both frequency and patterns of LOH differed greatly between the two tumor types. Although LOH was frequently detected in the special variant tumors, it was rare in the usual type tumors. LOH was detected in only 8 of the 18 usual tumors, with chromosomes 17, 13, and 2 being the most frequently affected (22%, 20%, and 19%, respectively). In contrast, LOH was detected in all cases of special variant tumors, with chromosomes 17p, 14, and 12 showing the highest LOH (83%, 77%, and 40%, respectively). Two cases of microsatellite instability (MI) were detected among the usual type tumors. These findings suggest that the clinicopathologic phenotypes observed in these tumor types are likely caused by different tumorigenic pathways that reflect alterations of different cancer-controlling genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158710     DOI: 10.1016/s0046-8177(97)90084-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Authors:  Alba Mota; Eva Colás; Pablo García-Sanz; Irene Campoy; Alejandro Rojo-Sebastián; Sonia Gatius; Ángel García; Luis Chiva; Sonsoles Alonso; Antonio Gil-Moreno; Xavier González-Tallada; Berta Díaz-Feijoo; August Vidal; Patrycja Ziober-Malinowska; Marcin Bobiński; Rafael López-López; Miguel Abal; Jaume Reventós; Xavier Matias-Guiu; Gema Moreno-Bueno
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

2.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

3.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

4.  SKY analysis revealed recurrent numerical and structural chromosome changes in BDII rat endometrial carcinomas.

Authors:  Eva Falck; Carola Hedberg; Karin Klinga-Levan; Afrouz Behboudi
Journal:  Cancer Cell Int       Date:  2011-06-27       Impact factor: 5.722

5.  Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.

Authors:  Evren Yilmaz; Meral Koyuncuoglu; Ilknur Bilkay Görken; Emre Okyay; Bahadir Saatli; Emine Cagnur Ulukus; Ugur Saygili
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.